About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 296 record(s)
Req # A-2023-03897
We read the article entitled "After pharma lobbying, minister intervened to suspend drug-price reform" published by the media "The Breach": https://breachmedia.ca/after-pharma-lobbying-minister-intervened-tosuspend-drug-price-reform/ We understand that someone from "The Breach" (its author Kelly Crowe or someone else) has requested information from the PMPRB to write the article. We cannot find this request through the archives of the Access to Information and Personal Information Online Request Service. We therefore request all communication, records and documents which were communicated in this request and/or relating to the information behind the aforementioned article which have been provided to The Breach or its employees.Organization: Patented Medicine Prices Review Board Canada
March 2023
Nothing to report this month
Organization: Nanaimo Port Authority
Req # A 2022_0007
The total compensation (salary + benefits) paid out to executives for the calendar years 2020, 2021 and 2022. Include a breakdown of the different types of benefits paid out including any performance or incentive pay received for each year. Please provide ranges if exact amounts cannot be provided. Please also provide a total number of executives at the corporation for each year.”Organization: Canada Development Investment Corporation
February 2023
Req # A 2022_0008
Documentation on the number of employees who have received pay increases during 2020, 2021 and 2022 (broken down by year), including step pay increases, but do not include pay raises due to promotions to new positions. Please also provide the amount of employees who received pay cuts during the same time periods, as well as corresponding amounts – but excluding those employees who left their positions.Organization: Canada Development Investment Corporation
February 2023
Req # A 2022_0010
Documentation on the amounts and number of employees who have received bonuses or other forms of performance incentives for 2020, 2021 and 2022. Provide the annual breakdown or equivalent for each calendar year (or fiscal if calendar not possible).Organization: Canada Development Investment Corporation
February 2023
Req # A-2023-02395
Copies of all correspondence and communications between the (then) acting chairperson of the Patented Medicines Prices Review Board Mélanie Bourassa-Forcier and Innovative Medicines Canada (IMC) between October 1, 2022 and December 5, 2022 regarding the PMPRB's new draft guidelines and the consultation process. Please include all responses to Innovative Medicines Canada (IMC)'s communications/correspondence from the (then) acting chairperson of the Patented Medicines Prices Review Board Mélanie Bourassa-Forcier.Organization: Patented Medicine Prices Review Board Canada
February 2023
Req # A-2022-09063
Copies of any emails sent by the Vice-chair regarding any of the following topics: (i) her resignation or intent to resign or the reasons for her resignation. (ii) the draft guidelines. (iii) the consultation process for the draft guidelines. (iv) the impact of the Merck Canada, IMC, and/or Alexion court decisions on the PMPRB, including its draft guidelines. From November 1, 2022 to December 5, 2022.Organization: Patented Medicine Prices Review Board Canada
February 2023
Req # A-2022-09228
All correspondence between PMPRB Board members and PMPRB staff pertaining to the October 2022 revised draft Guidelines and the resignation of the PMPRB Acting Chairperson, Mélanie Bourassa-Forcier. “Correspondence” includes written correspondence, call notes, email, text messaging, instant messaging, and any other form of electronic communication.Organization: Patented Medicine Prices Review Board Canada
February 2023
Req # A-2022-09229
All correspondence between the former PMPRB Acting Chairperson, Melanie Bourassa-Forcier, and the Minister of Health Jean-Yves Duclos (including the Minister’s staff), or Deputy Minister of Health Stephen Lucas (including the Deputy Minister’s staff), about the PMPRB October 2022 revised draft Guidelines and the resignation of PMPRB Acting Chairperson, Melanie Bourassa-Forcier. “Correspondence” includes written correspondence, call notes, email, text messaging, instant messaging, and any other form of electronic communication.Organization: Patented Medicine Prices Review Board Canada
February 2023
Req # A-2022-09230
All correspondence between PMPRB Executive Director Doug Clark and the Minister of Health Jean-Yves Duclos (including the Minister’s staff), or Deputy Minister of Health Stephen Lucas (including the Deputy Minister’s staff), about the PMPRB October 2022 revised draft Guidelines and the resignation of PMPRB Acting Chairperson, Melanie Bourassa-Forcier. “Correspondence” includes written correspondence, call notes, email, text messaging, instant messaging, and any other form of electronic communication.Organization: Patented Medicine Prices Review Board Canada
February 2023